Activity Overview
This online, on-demand virtual symposium brings together renowned experts in myeloproliferative neoplasms (MPNs). In this educational program, these experts update hematology-oncology health care professionals with the most recent data from key abstracts presented at major cancer conferences so that they can assess and apply these findings to their clinical practice and ultimately improve care for patients with hematologic malignancies.
This educational activity is an archive of the live symposium held on June 29, 2026.
Target Audience
Academic and community-based oncologists, hematologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with MPNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data for current and emerging therapies for patients with MPNs.
- Select personalized therapeutic strategies for patients with MPNs based on current paradigms and emerging, practice-changing clinical evidence.
- Implement appropriate strategies to monitor, mitigate, and manage toxicities associated with therapies for MPNs to improve treatment adherence and patient quality of life.
John O. Mascarenhas, MD
Director, Center of Excellence for Blood Cancers and Myeloid Disorders
Professor of Medicine
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Blueprint Medicines, Bristol Myers Squibb, Galecto, Geron, GSK, Incyte, Italfarmaco S.p.A., Karyopharm, Merck, Novartis, Pfizer, PharmaEssentia, Roche, Sobi, Sumitomo, Takeda; Grant/Research Funding: Ajax, DISC, Geron, Incyte, Italfarmaco S.p.A., Kartos, Karyopharm, Novartis, Pfizer, PharmaEssentia, Sobi
Claire Harrison, MD, DM, FRCP, FRCPath
Professor of Myeloproliferative Neoplasms
Guy’s and St Thomas’ NHS Foundation Trust
London, United Kingdom
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AOP, Galecto, GSK, Incyte, Janssen, Karyopharm, Menarini Stemline, Merck Sharp & Dohme, Novartis, Sobi, Syntara; Speakers Bureau: AOP Health, GSK, Menarini/Stemline, Merck Sharp & Dohme, Novartis; Grant/Research Funding: GSK; Ownership Interests in Privately Held Companies: Chakana Medical Ltd; Employee/Owner: Chakana Medical Ltd; Executive Role: Trustee, Blood Cancer UK; Medical Director, MPN Voice
Raajit Rampal, MD, PhD
Director, MPN and Rare Hematologic Disease Program
Department of Leukemia
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma (a Sobi Company), Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Zentalis Pharmaceuticals; Grant/Research Funding: Biomed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.